Patents Issued in March 20, 2018
  • Pharmaceutical tetracycline composition for dermatological use
    Patent number: 9918998
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: March 20, 2018
    Assignee: BioPharmX, Inc.
    Inventors: Xin Chen, Maiko C. Hermsmeier, Diana Lac, Douglas W. Thomas, Noymi Yam, Akira Yamamoto
  • Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis
    Patent number: 9918999
    Abstract: Method for preparing a medical solution, comprising the steps of a) providing a solution comprising one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a pH from 2.5 to 5.0, and b) terminal sterilization of said at least one compartment and the contents therein, is disclosed, as well as a solution used for preparing the medical solution, a container containing said solution, and use of said solution for the manufacture of a medicament for peritoneal dialysis.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: March 20, 2018
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Ola Carlsson, Tobjoern Linden, Anders Wieslander
  • Altering cancer cellular functions through proton mopping
    Patent number: 9919000
    Abstract: Proton mopping is a new anti-cancer therapeutic approach that disrupts cancer's immunologic balance. It results in the alteration of the pHi/pHe ratio (intracellular-extracellular) of the cancer cell, leading cancer to either normalcy or apoptosis. This technology deploys a chemical compound that has two parts, a glucose part to guide the molecule to the cancer site and a proton neutralizer to mop up the protons. Proof of the validity of this therapeutic approach came after using an existing chemical compound 2-[2(2-Aminoethoxy)ethoxy]ethyl a-D-mannopyranoside, C12H25NO8, which has the above mentioned properties. This compound is of the class of functionalized PEGylated glycosides, which are ligands for conjugation to biological molecules.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: March 20, 2018
    Inventor: Michael Theodore Lytinas
  • Drug carrier having L-DNA nanocage structure
    Patent number: 9919001
    Abstract: The present invention relates to a drug carrier having L-DNA nanocage structure prepared by using L-DNA, the mirror form of natural DNA, as a backbone. The drug carrier of the present invention has very superior cellular uptake efficiency and serum stability, so that it can be applied to deliver various drugs into cells usefully.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 20, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventor: Dae-Ro Ahn
  • Methods and constructs for compound delivery
    Patent number: 9919002
    Abstract: A construct for selectively delivering a compound of interest to a cell, includes (a) a bioresorbable polymer shell; (b) a nucleic acid duplex contained in said shell, the duplex comprising (i) an ATP binding nucleic acid, and (ii) a complementary nucleic acid hybridized to the ATP binding nucleic acid; (c) a compound of interest intercalated in or caged by the nucleic acid duplex; (d) optionally, but in some embodiments preferably, a cationic polymer in said polysaccharide shell; and (e) optionally, but in some embodiments preferably, a cell targeting ligand coupled to the polymer shell. The polymer shell is degraded in a cell of interest, or in the extracellular matrix of a tissue carrying said cell of interest, to release said duplex therein. The wherein said duplex is destabilized by binding of ATP in the cell of interest to release the compound of interest therein.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: March 20, 2018
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Zhen Gu, Ran Mo, Tianyue Jiang
  • Nicotinamide mononucleotide derivatives and their uses
    Patent number: 9919003
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 20, 2018
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
  • Polymer-based dialysate
    Patent number: 9919004
    Abstract: Embodiments described herein provide a dialysate comprising a polyglycerol. The polyglycerol may be of a molecular weight between about 0.15 kDa and about 60 kDa. Also provided herein is the use of the dialysate as a diffusion agent and as an osmotic agent.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: March 20, 2018
    Assignee: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Jayachandran Kizhakkedathu, Caigan Du, Gerald Da Roza, Asher Mendelson
  • Immune-modifying nanoparticles for the treatment of inflammatory diseases
    Patent number: 9919005
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: March 20, 2018
    Assignee: COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.
    Inventor: Daniel R. Getts
  • Compositions and methods for treating hyperkalemia
    Patent number: 9919006
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: March 20, 2018
    Assignee: Ardelyx, Inc.
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
    Patent number: 9919007
    Abstract: The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 20, 2018
    Assignee: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, Jr., David S. Wells
  • Method for treating age-related hearing loss (ARHL)
    Patent number: 9919008
    Abstract: A method for treating age-related hearing loss (ARHL) includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 20, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Josef M. Miller, José M. Juiz Gómez, Juan C. Alvarado-Romero, Verónica Fuentes-Santamaría
  • Production of red blood cells and platelets from stem cells
    Patent number: 9919009
    Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 20, 2018
    Assignees: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITY
    Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
  • Method for collecting functional cells in vivo with high efficiency
    Patent number: 9919010
    Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: March 20, 2018
    Assignees: GENOMIX CO., LTD., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Takenao Chino, Yasufumi Kaneda
  • Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome
    Patent number: 9919011
    Abstract: The present invention relates to a composition for treating inflammatory brain diseases, which includes stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention can be usefully applied to the treatment of inflammatory brain diseases, because the exosomes have outstanding therapeutic effects, including inhibiting cell death due to inflammation in nerve cells, increasing the survival rate in an inflammatory-brain-disease animal model, and substantially reducing brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 20, 2018
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park, Dong Kyung Sung, So Yoon Ahn
  • Method of identifying a biologically-active composition from a biofilm
    Patent number: 9919012
    Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: March 20, 2018
    Assignee: QUORUM INNOVATIONS, LLC
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
  • Use of tall oil fatty acid
    Patent number: 9919013
    Abstract: The present invention relates to use of a tall oil fatty acid in the modulation of microbial population of the animal digestive tract. The invention further relates to use of a feed supplement and a feed composition comprising tall oil fatty acid.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: March 20, 2018
    Assignee: Hankkija Oy
    Inventors: Juhani Vuorenmaa, Hannele Kettunen
  • Reproductive cell maintenance system
    Patent number: 9919014
    Abstract: Extracts obtained from the genus Hippophae or other plant sources or compositions produced by chemical or molecular biological techniques each having in common certain moieties in amounts effective when combined with reproductive cells to reduce the loss of function.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: March 20, 2018
    Assignee: Membrane Protective Technologies, Inc.
    Inventors: Lisa Ann Herickhoff, James August Herickhoff
  • Composition and method for inhibiting herpesviridae infections
    Patent number: 9919015
    Abstract: The present invention relates to a pharmaceutical composition when used for inhibiting a herpesviridae infection and/or providing relief from a herpesviridae infection in a subject. The composition includes an effective amount of an extract from a plant in the Asteraceae family.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: March 20, 2018
    Assignee: VIRATEC PTY LTD
    Inventors: Ross Walter Turner, Jonathan Tversky
  • Product and method of deploying kale derivatives for anti-cancer effects
    Patent number: 9919016
    Abstract: The present disclosure describes chemopreventative and/or chemotherapeutic compositions for inducing apoptosis in cancer cells which include kale and methods of inducing apoptosis in cancer cells utilizing the chemopreventative and/or chemotherapeutic compositions including kale.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: March 20, 2018
    Inventors: Bilal Qizilbash, Elizabeth Brandon
  • Biologically active substance-containing water-solubilizing preparation and method for producing the same
    Patent number: 9919017
    Abstract: An object of the present invention is to provide a water-solubilizing preparation that is obtained by convenient steps without use of a special apparatus such as a high-pressure homogenizer, does not impair the original properties of a water-based material even after being added to the material, has high dispersibility and transparency and excellent heat resistance and acid resistance, and can maintain stability. The water-solubilizing preparation of the present invention is a biologically active substance-containing water-solubilizing preparation comprising 1 to 50% by weight of an oily ingredient (A) containing a biologically active substance and oil, 10 to 98% by weight of a polyglycerin fatty acid ester (B) having an HLB value of 12.5 or larger, and 1 to 40% by weight of a surfactant (C) having an HLB value of 7 to 11.8.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: March 20, 2018
    Assignee: KANEKA CORPORATION
    Inventors: Takao Yamaguchi, Toshinori Ikehara
  • Compositions and methods for maintaining or enhancing homeostasis or function of female lower reproductive tract
    Patent number: 9919018
    Abstract: The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a Salvia extract. The compositions are useful for, for example, maintaining or enhancing female lower reproductive tract (LRT) homeostasis and physiological function. In particular, topical compositions of this disclosure can be formulated for use as a freshening, menopausal, fertility, and/or perineal composition.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: March 20, 2018
    Assignee: Fairhaven Health, LLC
    Inventors: Joanna E. Ellington, G. Dennis Clifton
  • Use of essential oil of oregano or of rosewood, or constituents thereof, in the cosmetic treatment of keratoses
    Patent number: 9919019
    Abstract: The present invention concerns various cosmetic uses of compositions comprising an essential oil or one of its constituents, preferably a major constituent, in the targeted treatment and prevention of benign keratoses, and more particularly keratoses induced by solar radiation on the skin of a subject. More particularly, the present invention concerns compositions based on the essential oil of oregano or of rosewood, or on linalool, thymol or carvacrol. The present invention also concerns therapeutic applications of a composition as described in the prevention or targeted treatment of actinic keratoses, essentially for prophylactic purposes.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: March 20, 2018
    Assignees: L'Oreal, Institut Curie, Centre National de la Recherche Scientifique
    Inventors: Laurent Marrot, Jérémie Soeur
  • Bioactive compound obtained from oil palm base materials
    Patent number: 9919020
    Abstract: This disclosure is directed to a novel bioactive compound obtained from oil palm based materials and compositions containing said bioactive compound. The bioactive compound obtained in accordance with the present invention has a molecular mass of 482. The bioactive compound also has potent HIV reverse transcriptase activity and antioxidant activity.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: March 20, 2018
    Assignee: Malaysian Palm Oil Board
    Inventors: Ravigadevi Sambanthamurthi, Yew Ai Tan, Syed Fairus Abu Bakar, Che Anishas Idris, Soon Sen Leow, Mohd Jamil Elias, Wan Saridah Wan Omar, Mohd Sofian Mohamad Ideris, Jabariah Md. Ali
  • Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions
    Patent number: 9919021
    Abstract: The present application presents novel peptidomimetic substituted hydroxyethylene compounds, which are inhibitors of beta amyloid cleavage enzyme, capable to permeate the brain and to achieve therapeutic concentrations in the target organ, the brain. These compounds are incorporated in pharmaceutical compositions and applied in the treatment or prophylaxis of neurological disorders or conditions and also other disorders or conditions including Down's syndrome and diabetes.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: March 20, 2018
    Assignee: IBET—INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA
    Inventors: Helder Joao Ferreira Vila Real, Ana Luisa Ferreira Simplicio, Olga Iranzo Casanova, Christopher David Maycock
  • Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
    Patent number: 9919022
    Abstract: Disclosed herein is a therapeutic intervention to prevent, reduce, or treat hemodialysis-associated skeletal muscle cramps by administering All receptor agonists or other pharmacologic agents that augment homeostatic responses to hemodialysis while preventing derecruitment of skeletal muscle capillaries.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: March 20, 2018
    Inventor: Arthur J. Atkinson, Jr.
  • Anti-androgen peptides and uses thereof in cancer therapy
    Patent number: 9919023
    Abstract: The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro)n-His-Pro-His-Ala-Arg-Ile-Lys]m-Y. The peptides are for medical use, in particular as anti-tumoral agents.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 20, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Ferdinando Auricchio, Antimo Migliaccio
  • Formulations of guanylate cyclase C agonists and methods of use
    Patent number: 9919024
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 20, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Pharmaceutical formulations of desmopressin
    Patent number: 9919025
    Abstract: Described herein are orodispersible pharmaceutical dosage forms of desmopressin comprising desmopressin free base or a pharmaceutically acceptable salt thereof, and one or more carriers, wherein at least one carrier is hydrolyzed gelatin in an open matrix network structure. Also described are methods of making and using such desmopressin orodispersible pharmaceutical dosage forms.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: March 20, 2018
    Assignee: FERRING B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 9919026
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: March 20, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Lipid nanoparticle of polymyxin
    Patent number: 9919027
    Abstract: A lipid nanoparticle that includes at least one antibiotic from the polymyxin family, a lipid fraction, and one or more surfactants. The lipid nanoparticle is useful in the prevention and/or treatment of respiratory tree infections.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: March 20, 2018
    Assignees: Biopraxis Research Aie, Praxis Pharmaceutical, S.A., Fundacio D'Investigacio Sanitaria De Les Illes Balears, Universidad Del Pais Vasco/Euskal Herriko Unibertsitatea, Universidad De Barcelona, Consejo Superior De Investigaciones Cientificas
    Inventors: Eusebio Gainza Lafuente, Angel Del Pozo Perez, Garazi Gainza Lucea, Oihane Ibarrola Moreno, Silvia Villullas Rincon, Raul Fernandez Plagaro, Daniel Bachiller Perez, Jose Luis Pedraz Munoz, Amaya Esquisabel Alegria, Marta Pastor Navarro, Ester Fuste Dominguez, Eulalia Sans Serramit Jana, Iraida Gil Martin
  • Autoclavable suspensions of cyclosporin A Form 2
    Patent number: 9919028
    Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: March 20, 2018
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Hongwen Ma Rivers, David A. Marsh, Michelle Luu
  • Methods and pharmaceutical compositions for the treatment of bacterial infections
    Patent number: 9919029
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections. In particular, the present invention relates to a Toll-like receptor (TLR) agonist for use in a method for the treatment of a bacterial infection in a subject in need thereof wherein the TLR agonist is administered to the subject in combination with at least one antibiotic.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: March 20, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Droit et de la Sante de Lille 2, Centre National de la Recherche Scientifique (CNRS), Institut Pasteur de Lille, Universite de Lille 1 Sciences et Technologies, ETH Zurich, Universidad de la Republica
    Inventors: Wolf-Dietrich Hardt, Patrick Kaiser, Jean-Claude Sirard, Christophe Carnoy, Delphine Fougeron, Jose Alejandro Chabalgoity, Natalia Munoz
  • Follistatin fusion proteins and uses thereof
    Patent number: 9919030
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with a follistatin antagonist and methods for managing patients treated with a follistatin antagonist.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: March 20, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventor: Matthew L. Sherman
  • Use of the insulin-like-growth factor 1 splice variant MGF for the prevention of myocardial damage
    Patent number: 9919031
    Abstract: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: March 20, 2018
    Assignee: THE BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS
    Inventors: Geoffrey Goldspink, Paul Goldspink
  • Method for administering a sustained release formulation
    Patent number: 9919032
    Abstract: The present invention provides pharmaceutical formulations for sustained release when administered at cold temperatures, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: March 20, 2018
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Susan Arnold, Christopher Prior, Lynne Georgopoulos
  • Dry growth hormone composition transiently linked to a polymer carrier
    Patent number: 9919033
    Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: March 20, 2018
    Assignee: Ascendis Pharma Endocrinology Division A/S
    Inventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
  • Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
    Patent number: 9919034
    Abstract: Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 20, 2018
    Assignee: TAMIR BIOTECHNOLOGY, INC.
    Inventor: Thomas W. Hodge, III
  • Pharmaceutical composition comprising bee venom-phospholipase A2 (bv-PLA2) for treating or preventing diseases related to degradation of abnormal regulatory T cell activity
    Patent number: 9919035
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 20, 2018
    Assignee: INIST ST CO., LTD.
    Inventors: Hyun Su Bae, Hyo Jung Lee, Gi Hyun Lee, Hyun Seong Kim, Soo Jin Park, Eun Sook Chung, Tae Won Choi
  • Identification of tumor-associated antigens for diagnosis and therapy
    Patent number: 9919036
    Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: March 20, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Dirk Usener
  • Immunogenic WT-1 peptides and methods of use thereof
    Patent number: 9919037
    Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: March 20, 2018
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: David A. Scheinberg, Tao Dao
  • Compositions comprising angiogenic factors and methods of use thereof
    Patent number: 9919038
    Abstract: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: March 20, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew Seavey, Yvonne Paterson, Paulo Maciag, Duane Sewell
  • Partner of SLD five 1 (PSF1)-derived peptide
    Patent number: 9919039
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: March 20, 2018
    Assignee: VASCULEAD INC.
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • Soluble recombinant plasmodium falciparum circumsporozoite protein, use in vaccines, methods of making and uses thereof
    Patent number: 9919040
    Abstract: The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli. Processes are provided for producing a soluble recombinant P. falciparum CSP from E. coli. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinant P. falciparum circumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: March 20, 2018
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY
    Inventor: Sheetij Dutta
  • PCV2 immunogenic compositions and methods of producing such compositions
    Patent number: 9919041
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Influenza virus mutants and uses therefor
    Patent number: 9919042
    Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: March 20, 2018
    Assignee: Flugen, Inc.
    Inventors: Pamuk Bilsel, Yasuko Hatta
  • Influenza virus mutants and uses therefor
    Patent number: 9919043
    Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: March 20, 2018
    Assignee: FluGen, Inc.
    Inventors: Pamuk Bilsel, Yasuko Hatta
  • Vaccines for diseases caused by viruses of the family of reoviridae
    Patent number: 9919044
    Abstract: The invention relates to methods for producing a propagation-competent strain of a mutant Reoviridae virus, and to a propagation-competent strain of a mutant Reoviridae virus that is obtainable by a method of the invention. The invention further relates to a propagation-competent strain of a mutant Reoviridae virus, comprising a deletion of a genetic region that is relevant for propagation of the virus, and to a vaccine, comprising a propagation-competent strain of a mutant Reoviridae virus.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: March 20, 2018
    Assignee: Stichting Wageningen Research
    Inventors: Petrus Antonius van Rijn, Hendricus Gerardus Petrus van Gennip, Sandra Gerarda Petra van de Water, Femke Feenstra
  • Herpes simplex virus vaccine compositions and methods of production and use thereof
    Patent number: 9919045
    Abstract: Vaccine compositions are disclosed for vaccinating a human or animal against herpes simplex virus infections. Also provided are methods of producing vaccines against herpes simplex virus and methods of using such vaccines to prevent or ameliorate herpes simplex virus-associated disease such as genital herpes.
    Type: Grant
    Filed: July 24, 2016
    Date of Patent: March 20, 2018
    Assignee: Sigmovir Biosystems, Inc.
    Inventors: Marina S. Boukhvalova, Jorge C. G. Blanco
  • Post release modification of viral envelopes
    Patent number: 9919046
    Abstract: Disclosed are methods of treatment of a subject, such as a method of vaccination, immunomodulation or gene therapy of a subject. These methods comprise administering to the subject a modified enveloped viral particle, wherein the modified enveloped viral particle has been obtained by a method comprising the steps of a) incubating a fluid containing enveloped viral particles with one or more reactants consisting of a hydrophilic target domain and a lipophilic membrane anchor domain, wherein the lipophilic membrane anchor domain becomes integrated into the lipid double layer of the envelope of the viral particle, wherein the hydrophilic target domain becomes exposed to the fluid; and b) separating enveloped modified viral particles from excessive reactants.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: March 20, 2018
    Assignee: VIN DE BONA TRADING CO. PTE LTD
    Inventors: John Dangerfield, Christoph Metzner
  • Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
    Patent number: 9919047
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: March 20, 2018
    Assignees: SILLAJEN, INC., SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim